

Aventis Pharma Limited

13th December 2010

Manager, Listing
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra East
Mumbai 400 051

Dear Sirs,

Re: Sale of 49% shareholding in Chiron Behring Vaccines Private Limited

As you are aware, we are holding 4,900,000 shares in Chiron Behring Vaccines Private Limited (CBVPL) representing 49% of the paid up capital of CBVPL. The balance 51% shares are held by our joint venture partner, Novartis Vaccines & Diagnostics Inc. CBVPL manufactures the anti-rabies vaccine Rabipur at its plant in Ankleshwar, which was until February 2009 distributed in India by our Company and is presently distributed by Novartis Healthcare Private Limited.

We have now to inform you that we have agreed with our joint venture partner, Novartis Vaccines & Diagnostics Inc. to sell our 49% shareholding to its nominee, Novartis Pharma AG and exit the joint venture. The purchase price agreed to be paid to us is US Dollars 22.399 million. The Board of Directors of our Company has approved the sale of the said 49% shareholding. The sale of the said shareholding is expected to close before 31st December 2010.

We have agreed to continue to provide certain utilities and services to the Ankleshwar plant of CBVPL for a period of three years from the date of closing on mutually agreed terms.

Upon the closing of the sale of the shareholding, the pending disputes between the Company and Novartis Vaccines & Diagnostics Inc./CBVPL shall stand resolved and all legal proceedings filed in connection with such disputes shall be unconditionally withdrawn.

Thanking you,

Yours faithfully,
AVENTIS PHARMA LIMITED



DR. S. AYYANGAR
MANAGING DIRECTOR